Dialogues on AI Digital Pathology is a series of webinars and podcasts that look into the role of AI in drug discovery and treatment development efforts for Nonalcoholic Steatohepatitis (NASH). Do click onto the webinars/podcasts to listen to our guest speakers, who are clinical and industry experts in the field of liver diseases. Follow/Subscribe to our Podcasts now!

 anchor badge spotify podcast badge wht grn 660x160  US UK Apple Podcasts Listen Badge CMYK  EN Google Podcasts Badge 8x 

   

Podcast Cover Art 03 Nov 2020

[Full Podcast] Episode 3 with Dr. Suneil Hosmane - Dialogues...

Date: 03 Nov 2020

Listen to our guest, Dr. Suneil Hosmane (Executive Vice President and Global Head of Diagnostics at GENFIT), as he speaks about the role of AI digital pathology, the latest NIS4 blood-based diagnostic test by Genfit and how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts in NASH clinical trials today that could ultimately transform the NASH clinical care pathway. 

 

Read More
Podcast trailer 28 Oct 2020

PODCAST TRAILER FOR EP 3: Dialogues on AI Digital Pathology

Date: 28 Oct 2020

[Podcast Trailer Alert - Dialogues on AI Digital Pathology]

Episode 3 is coming up real soon! Here's a sound bite from our guest, Dr. Suneil Hosmane (Executive Vice President and Global Head of Diagnostics at GENFIT), who will share his views on how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts and benefit patient outcomes.

Watch out for our updates next week when Episode 3 goes Live! Do remember to Subscribe to or Follow us on Anchor, Apple Podcasts, Spotify and Google Podcasts!

Read More
Podcast Cover Art 13 Oct 2020

[Full Podcast] Episode 2 with Dr. David Kleiner feat. Dr Dea...

Date: 13 Oct 2020

In Episode 2 of Dialogues on Digital Pathology, we speak to Dr. David Kleiner, Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, from the Center for Cancer Research at the National Cancer Institute. 

Dr. Kleiner will be sharing his views on AI digital pathology and how it can work hand-in-hand with liver pathologists to empower NASH drug development and clinical practice. During the Q&A segment, Dr. Kleiner will be joined by supporting guest, Dr. Dean Tai, Chief Scientific Officer of HistoIndex, who will provide his insights on the role of machine learning in reinforcing important diagnostic decisions for NASH. 

Read More
Podcast trailer 08 Oct 2020

PODCAST TRAILER FOR EP 2: Dialogues on AI Digital Pathology

Date: 08 Oct 2020

Watch out for our upcoming episode next week with our guest, Dr. David Kleiner, Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, from the Center for Cancer Research at the National Cancer Institute. Dr. Kleiner will be sharing his views on AI digital pathology and how it can work hand-in-hand with liver pathologists to empower NASH drug development and clinical practice.

 

Read More
Podcast Cover Art 17 Aug 2020

[Full Podcast] Episode 1 with Dr Stephen Harrison - Dialogu...

Date: 17 Aug 2020

In our inaugural episode of Dialogues on AI Digital Pathology, we speak to Dr Stephen Harrison (Medical Director of Pinnacle Clinical Research) on the role AI digital pathology can play in current NASH drug development.

 

Read More
Podcast trailer 12 Aug 2020

PODCAST TRAILER: Dialogues on AI Digital Pathology

Date: 12 Aug 2020

Welcome to Dialogues on AI Digital Pathology. In this Podcast series, we’ll be speaking to medical and industry experts, who will be sharing their thoughts on the evolving trends of AI digital pathology and its role in finding effective treatments for Nonalcoholic Steatohepatitis (NASH). We look forward to bringing you more insights on AI digital pathology from our guest speakers, so do stay tuned!

Read More
LinkedInWebinar3 14 Jul 2020

WEBINAR: NASH Animal Models and their Clinical Relevance - Q...

Date: 14 Jul 2020

Catch this webinar on preclinical NASH, as Wuxi Apptec and HistoIndex share their experience in their efforts to determine the clinical relevance and translatability of NASH models and hepatic fibrosis in particular.

Read More